An ERR agonist that mimics the cellular effects of aerobic exercise without physical activity.
A potent agonist of Estrogen-Related Receptors alpha and gamma (ERRα/γ) — transcription factors that govern the cellular adaptations to aerobic exercise. ERR activation drives expression of PGC-1α, increases mitochondrial biogenesis, upregulates fatty acid oxidation enzymes, and enhances oxidative phosphorylation capacity — replicating the molecular signature of endurance exercise training.
Published research in Nature Communications (2023) showed SLU-PP-332 improved endurance performance in sedentary mice and partially replicated transcriptional changes of aerobic exercise training. The concept of 'exercise in a pill' has attracted significant scientific attention.
ERR agonists could be relevant for populations unable to exercise (heart failure, mobility impairment, sarcopenia) as well as for combination use with lifestyle interventions.